Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

swedish orphan biovitrum ab - loncastuximab tesirine - lymphoma, large b-cell, diffuse; lymphoma, b-cell - Αντινεοπλασματικοί παράγοντες - zynlonta as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl), after two or more lines of systemic therapy.

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

gilead sciences ireland uc - idelalisib - lymphoma, non-hodgkin; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, other antineoplastic agents - zydelig is indicated in combination with an anti‑cd20 monoclonal antibody (rituximab or ofatumumab) for the treatment of adult patients with chronic lymphocytic leukaemia (cll):who have received at least one prior therapy, oras first line treatment in the presence of 17p deletion or tp53 mutation in patients who are not eligible for any other therapies. zydelig is indicated as monotherapy for the treatment of adult patients with follicular lymphoma (fl) that is refractory to two prior lines of treatment.

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - tafasitamab - lymphoma, large b-cell, diffuse - Αντινεοπλασματικοί παράγοντες - minjuvi is indicated in combination with lenalidomide followed by minjuvi monotherapy for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) who are not eligible for autologous stem cell transplant (asct).

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

roche registration gmbh  - glofitamab - lymphoma, large b-cell, diffuse - Αντινεοπλασματικοί παράγοντες - columvi as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl), after two or more lines of systemic therapy.

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - epcoritamab - lymphoma, large b-cell, diffuse - Αντινεοπλασματικοί παράγοντες - tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) after two or more lines of systemic therapy.

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

krka, d.d., novo mesto  - lenalidomide hydrochloride monohydrate - multiple myeloma; myelodysplastic syndromes; lymphoma, follicular; lymphoma, mantle-cell - Ανοσοκατασταλτικά - multiple myelomalenalidomide krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) ενδείκνυται για τη θεραπεία ενηλίκων ασθενών με μη προθεραπευμένο πολλαπλούν μυέλωμα που δεν είναι κατάλληλοι για μεταμόσχευση. lenalidomide krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. mantle cell lymphomalenalidomide krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4. 4 και 5. follicular lymphomalenalidomide krka in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) ενδείκνυται για τη θεραπεία ενηλίκων ασθενών με μη προθεραπευμένο πολλαπλούν μυέλωμα που δεν είναι κατάλληλοι για μεταμόσχευση. lenalidomide krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. mantle cell lymphomalenalidomide krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4. 4 και 5. follicular lymphomalenalidomide krka in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

ΜΙΝΕΡΒΑ ΦΑΡΜΑΚΕΥΤΙΚΗ Α.Ε. Λ. ΚΗΦΙΣΣΟΥ 132, 12131 ΠΕΡΙΣΤΕΡΙ 5711211 - retinol palmitate; dexpanthenol - cream (ΚΡΕΜΑ) - 7,055iu/g+20mg - retinol palmitate 7,055iu; dexpanthenol 20mg - other emollients and protectives - other emollients and protectives

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

bausch + lomb ireland limited, ireland 3013 lake drive, d24ppt dublin + 48 539 772 299 - oxymetazoline hydrochloride - naspr.sol (ΡΙΝΙΚΟ ΕΚΝΕΦΩΜΑ, ΔΙΑΛΥΜΑ) - 22mcg/dose - oxymetazoline hydrochloride 0,5mg - oxymetazoline

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

ΤΑΡΓΚΕΤ ΦΑΡΜΑ ΜΟΝΟΠΡΟΣΩΠΗ ΕΤΑΙΡΕΙΑ ΠΕΡΙΟΡΙΣΜΕΝΗΣ ΕΥΘΥΝΗΣ Δ.Τ. target pharma ΜΟΝΟΠΡΟΣΩΠΗ ΕΠΕ Μενάνδρου 54,, 104 31 104 31, Αθήνα 210.5224830 - salicylic acid - cut.sol (ΔΕΡΜΑΤΙΚΟ ΔΙΑΛΥΜΑ) - 10% w/w - salicylic acid 100mg - salicylic acid; other antipsoriatics for topical use - other antipsoriatics for topical use